Pharmacology at Your Fingertips: Terry’s Corner Launches
- GPCR News
- Jul 2
- 2 min read
Updated: Jul 3
Welcome Back, Discovery Drivers
Terry’s Corner is live, on-demand pharmacology built for drug discovery. Yamina’s Corner opens for strategic consulting, and our partner Celtarys unveils a robust TR-FRET assay for CBRs. Plus: must-read chemokine and PTH1R papers, and new momentum across biotech—from Superluminal to Neurocrine to novel GLP-1 contenders.
Dr.GPCR Updates
Terry’s Corner is Live - Pharmacology at your fingertips
Terry’s Corner is now open! Explore 10 on-demand lessons by Dr. Terry Kenakin with short videos, clear summaries, and curated references. New and unique lessons are released weekly on Tuesday. Elevate your drug discovery program with 45+ lessons yearly.
Premium Members: Get your exclusive discount code in this week’s full edition of the this newsletter accessible at the bottom of this email.
Yamina’s Corner Is Live – Are you drowning in disorganized data?
Yamina’s Corner delivers GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking programs from hit validation through development candidate selection and beyond. With a biology-first strategy, embedded execution, and scalable systems, it turns scattered data into decisions, accelerating your path to a successful preclinical program. Because even the best data means nothing without structure. That’s the Lego Bucket Problem.
CELT-335 - Celtarys Validates New Assay for CB1/CB2 Screening
Dr. GPCR partner Celtarys Research has validated a TR-FRET assay for cannabinoid receptor ligands using their probe CELT-335. With nanomolar affinity, high specificity, and a strong signal-to-noise profile, this non-radioactive, cell-compatible platform is ready for your next SAR-driven screening campaign.
Read The Full Article
GPCR Publication Highlights
Chemokine–GPCR Selectivity Unveiled
Sequence- and structure-based analysis reveals how conserved and variable regions across chemokines and their receptors drive selectivity and promiscuity, paving the way for rational ligand design.
Cryo-EM structures of Gq-bound PTH1R uncover glycan and loop-based mechanisms shaping G-protein preference, offering a path toward signaling-biased osteoporosis therapies.
Distinct Ligand Activation in NMBR
Simulations show how two ligands differently activate class A GPCR NMBR, with allosteric communication hubs modulating signaling, advancing antipruritic drug strategies.
Want the full breakdown and your discount code for Terry's Corner?
Better pharmacology leads to better decisions—unlock it now with Terry’s Corner.
Stay curious,
The Dr. GPCR Team
Join Our Newsletter!
To start receiving our newsletter in your inbox every Thursday, follow these simple steps:
Select the Log In / Sign Up option located at the top right corner of the header.
Select 'New to this site? Sign Up'
Complete the registration form.
Stay updated with the latest news and insights by signing up today!
Comments